These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 21435153)

  • 1. A pilot study of endorectal magnetic resonance imaging and magnetic resonance spectroscopic imaging changes with dutasteride in patients with low risk prostate cancer.
    Chung HT; Noworolski SM; Kurhanewicz J; Weinberg V; Roach Iii M
    BJU Int; 2011 Oct; 108(8 Pt 2):E164-70. PubMed ID: 21435153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MAPPED study design: a 6 month randomised controlled study to evaluate the effect of dutasteride on prostate cancer volume using magnetic resonance imaging.
    Robertson NL; Moore CM; Ambler G; Bott SR; Freeman A; Gambarota G; Jameson C; Mitra AV; Whitcher B; Winkler M; Kirkham A; Allen C; Emberton M
    Contemp Clin Trials; 2013 Jan; 34(1):80-9. PubMed ID: 23085153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of locally recurrent prostate cancer after cryosurgery: evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy.
    Parivar F; Hricak H; Shinohara K; Kurhanewicz J; Vigneron DB; Nelson SJ; Carroll PR
    Urology; 1996 Oct; 48(4):594-9. PubMed ID: 8886066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer--results from a 4-month pre-radical prostatectomy study.
    Gleave M; Qian J; Andreou C; Pommerville P; Chin J; Casey R; Steinhoff G; Fleshner N; Bostwick D; Thomas L; Rittmaster R
    Prostate; 2006 Nov; 66(15):1674-85. PubMed ID: 16927304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate.
    Iczkowski KA; Qiu J; Qian J; Somerville MC; Rittmaster RS; Andriole GL; Bostwick DG
    Urology; 2005 Jan; 65(1):76-82. PubMed ID: 15667867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.
    Andriole GL; Marberger M; Roehrborn CG
    J Urol; 2006 May; 175(5):1657-62. PubMed ID: 16600723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging.
    Coakley FV; Chen I; Qayyum A; Westphalen AC; Carroll PR; Hricak H; Chen MH; Kurhanewicz J
    BJU Int; 2007 Jan; 99(1):41-5. PubMed ID: 17227490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential of magnetic resonance spectroscopic imaging in predicting absence of prostate cancer in men with serum prostate-specific antigen between 4 and 10 ng/ml: a follow-up study.
    Kumar R; Nayyar R; Kumar V; Gupta NP; Hemal AK; Jagannathan NR; Dattagupta S; Thulkar S
    Urology; 2008 Oct; 72(4):859-63. PubMed ID: 18329078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dutasteride improves objective and subjective disease measures in men with benign prostatic hyperplasia and modest or severe prostate enlargement.
    Gittelman M; Ramsdell J; Young J; McNicholas T
    J Urol; 2006 Sep; 176(3):1045-50; discussion 1050. PubMed ID: 16890688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Kurko B
    Urology; 2006 Jul; 68(1):116-20. PubMed ID: 16844453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
    Andriole GL; Roehrborn C; Schulman C; Slawin KM; Somerville M; Rittmaster RS
    Urology; 2004 Sep; 64(3):537-41; discussion 542-3. PubMed ID: 15351586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
    Rittmaster R; Hahn RG; Ray P; Shannon JB; Wurzel R
    Urology; 2008 Oct; 72(4):808-12. PubMed ID: 18718641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of endorectal magnetic resonance spectroscopic imaging in two different Gleason scores in prostate cancer.
    Nagarajan R; Margolis D; McClure T; Raman S; Thomas MA
    Med Princ Pract; 2011; 20(5):444-8. PubMed ID: 21757934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study.
    Montorsi F; Henkel T; Geboers A; Mirone V; Arrosagaray P; Morrill B; Black L
    Int J Clin Pract; 2010 Jul; 64(8):1042-51. PubMed ID: 20487046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience improves staging accuracy of endorectal magnetic resonance imaging in prostate cancer: what is the learning curve?
    Latchamsetty KC; Borden LS; Porter CR; Lacrampe M; Vaughan M; Lin E; Conti N; Wright JL; Corman JM
    Can J Urol; 2007 Feb; 14(1):3429-34. PubMed ID: 17324322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study.
    van Gils MP; Hessels D; Peelen WP; Vergunst H; Mulders PF; Schalken JA
    Prostate; 2009 Nov; 69(15):1624-34. PubMed ID: 19588525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial.
    Aubin SM; Reid J; Sarno MJ; Blase A; Aussie J; Rittenhouse H; Rittmaster RS; Andriole GL; Groskopf J
    Urology; 2011 Aug; 78(2):380-5. PubMed ID: 21820580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy.
    Sciarra A; Panebianco V; Ciccariello M; Salciccia S; Cattarino S; Lisi D; Gentilucci A; Alfarone A; Bernardo S; Passariello R; Gentile V
    Clin Cancer Res; 2010 Mar; 16(6):1875-83. PubMed ID: 20197480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial.
    Fleshner N; Gomella LG; Cookson MS; Finelli A; Evans A; Taneja SS; Lucia MS; Wolford E; Somerville MC; Rittmaster R;
    Contemp Clin Trials; 2007 Nov; 28(6):763-9. PubMed ID: 17573244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dutasteride monotherapy in men with serologic relapse following radical therapy for adenocarcinoma of the prostate: a pilot study.
    Perrotti M; Jain R; Abriel LM; Baroni TE; Corbett AB; Tenenbaum SA
    Urol Oncol; 2012; 30(2):133-8. PubMed ID: 20800512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.